Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Curr Res Transl Med
; 71(4): 103421, 2023.
Article
em En
| MEDLINE
| ID: mdl-38016419
ABSTRACT
Genetic data are becoming increasingly essential in the management of hematological neoplasms as shown by two classifications published in 2022 the 5th edition of the World Health Organization Classification of Hematolymphoid Tumours and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Genetic data are particularly important for acute myeloid leukemias (AMLs) because their boundaries with myelodysplastic neoplasms seem to be gradually blurring. The first objective of this review is to present the latest updates on the most common cytogenetic abnormalities in AMLs while highlighting the pitfalls and difficulties that can be encountered in the event of cryptic or difficult-to-detect karyotype abnormalities. The second objective is to enhance the role of cytogenetics among all the new technologies available in 2023 for the diagnosis and management of AML.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
/
Histiocitose
Limite:
Humans
Idioma:
En
Revista:
Curr Res Transl Med
Ano de publicação:
2023
Tipo de documento:
Article